Kangtai Biological Announces Strategic Collaboration with Daxing District Government and AstraZeneca in Vaccine Development

Shanghai Securities News China Securities Network News – Shenzhen Kangtai Biological Products Co., Ltd. announced on April 2 that recently, its wholly-owned subsidiary Minhai Biologics, Daxing District People's Government of Beijing, and AstraZeneca held a signing ceremony for the "Strategic Cooperation Memorandum" on March 25. Authorized representatives of all parties signed the "Strategic Cooperation Memorandum," and the document was officially stamped recently, making the above-mentioned "Strategic Cooperation Memorandum" officially effective. Shenzhen Kangtai Biological Products Co., Ltd. stated that the cooperating parties will jointly explore establishing a long-term strategic cooperation in the vaccine field, discuss mutually beneficial cooperation models, and jointly promote the localization and market access in China of innovative product pipelines from both AstraZeneca and Minhai Biologics. This move aims to accelerate the early benefit of global scientific innovation achievements for patients in China while promoting the introduction of advanced overseas vaccine production management technologies, supporting the domestic and international cooperation and development of innovative vaccine products in China. (Reporter: He Xinyi)